Clinical Trials
12 trialsNCT07583316 2026-05-13
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT07518160 2026-04-08
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT07461662 2026-03-10
EBUS
University of Mississippi Medical Center
Phase NA Not yet recruiting
NCT07423117 2026-02-20
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
Phase 1 Not yet recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT07303881 2025-12-26
JACKPOT22
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT07260058 2025-12-02
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06725537 2025-01-15
CA209-1529
D'Or Institute for Research and Education
Not yet recruiting
NCT06738680 2024-12-18
PROFIL-1
University Hospital, Brest
Not yet recruiting
NCT06594874 2024-09-19
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting